ACRS SEC फाइलिंग - Aclaris Therapeutics, Inc.- वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट, प्रॉस्पेक्टस

मूलभूत आँकड़े

LEI	5493000B2LQ9QTW1DF52
CIK	1557746

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aclaris Therapeutics, Inc.

SEC Filings (Chronological Order)

यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।

August 7, 2025	EX-99.1	Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate IT Exhibit 99.1 Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target - - Advanced Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) into Phase 2 Trial in Atopic Dermatitis (AD); Pati
August 7, 2025	10-Q	7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Aclaris Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commissi
July 29, 2025	EX-99.1	3 ATI-2138 Oral Small Molecule Covalent ITK & JAK3 Inhibitor for I&I Disease • Investigational oral compound which interrupts T cell receptor (TCR) signaling by inhibiting ITK and JAK3 signaling of common γ chain cytokines in lymphocytes (including I Exhibit 99.1 ATI-2138 Phase 2a Top-Line Results July 29, 2025 2 Disclaimer and Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticip
July 29, 2025	EX-99.2	Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints - Primary Endpoint Analysis Conf Exhibit 99.2 ‌ Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints - Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Sh
July 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 Aclaris Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commissio
June 30, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commissio
June 30, 2025	EX-99.1	2 Disclaimer and Cautionary Note Regarding Forward -Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Lit Exhibit 99.1 Corporate Overview June 2025 EMPOWERING PATIENTS THROUGH THERAPEUTIC INNOVATION 2 Disclaimer and Cautionary Note Regarding Forward -Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be ident
June 5, 2025	EX-10.3	Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement used in connection with the Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan. Exhibit 10.3 ACLARIS THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2025 EQUITY INCENTIVE PLAN) Aclaris Therapeutics, Inc. (the “Company”), pursuant to Section 6(b) of the Company’s 2025 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”
June 5, 2025	EX-10.1	Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan. Exhibit 10.1 ACLARIS THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN 1.General. (a)Successor to Prior Plan. This Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan (as it may be amended from time to time, the “Plan”) is intended as the successor to the Aclaris Therapeutics, Inc. 2015 Equity Incentive Plan, as amended from time to time (the “Prior Plan”). From and after 12:01 a.m. Eastern Time on
June 5, 2025	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACLARIS THERAPEUTICS, INC. ACLARIS THERAPEUTICS, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: The name of the Company is Aclaris Therapeutics, Inc. SECOND:The Company’s original Certificate of Incorporation was fi
June 5, 2025	S-8	As filed with the U.S. Securities and Exchange Commission on June 5, 2025 As filed with the U.S. Securities and Exchange Commission on June 5, 2025 Registration No. 333-       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ACLARIS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-0571712 (State or other jurisdiction of Incorporation or organizati
June 5, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Aclaris Therapeutics, Inc.
June 5, 2025	EX-10.2	Form of Stock Option Grant Notice and Option Agreement used in connection with the Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan. Exhibit 10.2 Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan Stock Option Grant Notice Aclaris Therapeutics, Inc. (the “Company”), pursuant to its 2025 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notice,
June 5, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commission
May 8, 2025	EX-10.4	Tenth Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.4 ACLARIS THERAPEUTICS, INC. TENTH AMENDED & RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Aclaris Therapeutics, Inc. (the “Company”) (each such member, an “Eligible Director”) will receive the compensation described in this Ninth Amended & Restated Non-Employee Director Compensation Polic
May 8, 2025	EX-99.2	2 Disclaimer and Cautionary Note Regarding Forward -Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Lit Exhibit 99.2 Corporate Overview May 2025 EMPOWERING PATIENTS THROUGH THERAPEUTIC INNOVATION 2 Disclaimer and Cautionary Note Regarding Forward -Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identi
May 8, 2025	EX-10.3	Employment Agreement, dated as of April 28, 2025, by and between the Registrant and Jesse Hall. Exhibit 10.3 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Employment Agreement”), effective as of April 28, 2025 (“Agreement Effective Date”), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Employer”) and Jesse Hall (“Executive”). WHEREAS, Executive desires to provide services to Employer and Employer desires to retain t
May 8, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commission
May 8, 2025	EX-99.1	Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Exhibit 99.1 Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Oppor
May 8, 2025	10-Q	7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 24, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 24, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
April 14, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 5, 2025	CORRESP	March 5, 2025 March 5, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell Re: Aclaris Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 Filed: February 27, 2025 File No. 333-285370 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby request
February 27, 2025	EX-10.27	Collaboration Agreement, dated as of November 18, 2024, by and among the Registrant, Biosion, Inc. and Chia Tai Tianqing Pharmaceutical Group, Co., Ltd. Execution Version Exhibit 10.27 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN OMITTED. COLLABORATION AGREEMENT THIS COLLABORATION AGREEMENT (this “Agreement”) is entered into as of November 18, 2024 (the “Effective Date”). PARTIE
February 27, 2025	EX-4.6	Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 ACLARIS THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ACLARIS THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ACLARIS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organiz
February 27, 2025	EX-10.26	Exclusive License Agreement, dated as of November 18, 2024, by and between the Registrant and Biosion, Inc. Exhibit 10.26 EXECUTION VERSION CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN OMITTED EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN BIOSION, INC. AND ACLARIS THERAPEUTICS, INC. November 18, 2024 TABLE OF CONTENTS Article 1 Definitio
February 27, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Aclaris Therapeutics, Inc.
February 27, 2025	EX-10.21	Employment Agreement, dated as of February 26, 2025, by and between the Registrant and Neal Walker. Exhibit 10.21 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Employment Agreement”), effective as of February 26, 2025 (“Agreement Effective Date”), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Employer”) and Neal Walker (“Executive”). WHEREAS, Executive desires to continue to provide services to Employer and Employer de
February 27, 2025	EX-19.1	Insider Trading Policy, effective as of February 26, 2025. Exhibit 19.1 POLICY POL-00048 PAGE: 1 of 9 EFFECTIVE DATE: 26 Feb 2025 INSIDER TRADING POLICY 1. PURPOSE Aclaris Therapeutics, Inc. (together with its subsidiaries, the “Company”) has adopted this Insider Trading Policy (this “Policy”) to prevent “insider trading”. Simply stated, insider trading occurs when a person uses “material non-public information” (as defined in Section 3.2 below) to make d
February 27, 2025	EX-99.1	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data from CTTQ’s Exhibit 99.1 Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data from CTTQ’s Phase 2 Studies of Bosakitug (ATI-045) in Chinese Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Expe
February 27, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commi
February 27, 2025	EX-10.28	Form of Common Stock Purchase Warrant Agreement issued on November 18, 2024. Exhibit 10.28 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN OMITTED. THIS WARRANT AND THE SECURITIES TO BE ISSUED UPON ITS EXERCISE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR
February 27, 2025	EX-4.5	Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 ACLARIS THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF ACLARIS THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ACLARIS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and ex
February 27, 2025	EX-4.7	Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.7 ACLARIS THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ACLARIS THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ACLARIS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organiz
February 27, 2025	EX-4.3	Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.3 ACLARIS THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 7
February 27, 2025	S-3	As filed with the Securities and Exchange Commission on February 27, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 27, 2025 Registration No.
February 27, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission file number 001-37581 ACLARIS THERAPEUTICS, INC. Incorporated under the Laws of the I.R.S. Employer Identification No. State of Delaware 46-0571712 701 Lee Road
February 27, 2025	EX-10.24	Amended and Restated Sales Agreement dated as of February 27, 2025, by and among the Registrant, Leerink Partners LLC and Cantor Fitzgerald & Co. (incorporated by reference to Exhibit 10.24 to the Registrant’s Annual Report on Form 10-K (File No. 001-37581), filed with the SEC on February 27, 2025). Exhibit 10.24 ACLARIS THERAPEUTICS, INC. Shares of Common Stock ($0.00001 par value per share) AMENDED AND RESTATED SALES AGREEMENT February 27, 2025 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 CANTOR FITZGERALD & CO. 110 East 59th Street New York, New York 10022 Ladies and Gentlemen: Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and L
February 12, 2025	EX-99.1	JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p25-0224exhibit991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of fi
January 13, 2025	EX-99.1	2 Disclaimer and Cautionary Note Regarding Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Liti Exhibit 99.1 I N V E S T O R P R E S E N T A T I O N Corporate Overview January 2025 2 Disclaimer and Cautionary Note Regarding Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by
January 13, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commis
December 31, 2024	424B3	35,555,555 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-283942 PROSPECTUS 35,555,555 Shares of Common Stock This prospectus covers the offer and resale by the selling stockholders identified in this prospectus or their donees, pledgees, transferees or other successors-in-interest, or the selling stockholders, of up to an aggregate of 35,555,555 shares of our common stock, par val
December 27, 2024	CORRESP	December 27, 2024 December 27, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama Re: Aclaris Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 Filed: December 19, 2024 File No. 333-283942 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby
December 19, 2024	S-3	As filed with the Securities and Exchange Commission on December 19, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 19, 2024 Registration No.
December 19, 2024	EX-FILING FEES	Filing Fee Table. Calculation of Filing Fee Tables S-3 Aclaris Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effectiv
November 27, 2024	EX-FILING FEES	Filing Fee Table Calculation of Filing Fee Tables S-8 Aclaris Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.00001 per share, Aclaris Therapeutics, Inc. 2024 Inducement Plan Other 2,000,00
November 27, 2024	S-8	As filed with the U.S. Securities and Exchange Commission on November 27, 2024 As filed with the U.S. Securities and Exchange Commission on November 27, 2024 Registration No. 333-          UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ACLARIS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-0571712 (State or other jurisdiction of Incorporation or or
November 25, 2024	SC 13G	ACRS / Aclaris Therapeutics, Inc. / Biosion, Inc. Passive Investment SC 13G 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ACLARIS THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, $0.00001 PAR VALUE (Title of Class of Securities) 00461U105 (CUSIP Number) NOVEMBER 18, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to
November 22, 2024	SC 13G	ACRS / Aclaris Therapeutics, Inc. / Rock Springs Capital Management LP Passive Investment SC 13G 1 rocksprings-acrs111824.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 00461U105 (CUSIP Number) November 18, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr
November 21, 2024	SC 13G	ACRS / Aclaris Therapeutics, Inc. / Vivo Opportunity Fund Holdings, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 00461U105 (CUSIP Number) November 19, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule
November 21, 2024	EX-99.1	Joint Filing Statement EX-99.1 2 ea022215601ex99-1aclaris.htm JOINT FILING STATEMENT EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint fil
November 18, 2024	EX-10.6	Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement used in connection with the Aclaris Therapeutics, Inc. 2024 Inducement Plan. Exhibit 10.6 ACLARIS THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2024 INDUCEMENT PLAN) Aclaris Therapeutics, Inc. (the “Company”), pursuant to Section 6(b) of the Company’s 2024 Inducement Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award
November 18, 2024	EX-10.4	Aclaris Therapeutics, Inc. 2024 Inducement Plan. Exhibit 10.4 ACLARIS THERAPEUTICS, INC. 2024 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: NOVEMBER 16, 2024 1.GENERAL. (a)Eligible Award Recipients. Awards under the Plan may only be granted to Employees who satisfy the standards for inducement grants under Rule 5635(c)(4) of the NASDAQ Listing Rules. A person who previously served as an Employee or Director will not be eligible to receive A
November 18, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2024 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commi
November 18, 2024	EX-99.1	Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - Enhances Aclaris’ pipeline with complementary biologics portfolio - - Expands leadership team with ad Exhibit 99.1 Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - Enhances Aclaris’ pipeline with complementary biologics portfolio - - Expands leadership team with addition of seasoned biotech executives - - Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSW
November 18, 2024	EX-99.3	© Copyright 2024 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Cautionary Note Regarding Forward-Looking Statements 2 Any statements contained in this presentation that do not desc Exhibit 99.3 © Copyright 2024 Aclaris Therapeutics, Inc. All rights reserved Confidential © Copyright 2024 Aclaris Therapeutics, Inc. All rights reserved Corporate Overview November 2024 © Copyright 2024 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Cautionary Note Regarding Forward-Looking Statements 2 Any statements contained
November 18, 2024	EX-10.1	Form of Securities Purchase Agreement, dated November 18, 2024, by and between the Company and the investors named therein. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 18, 2024, by and among Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and delive
November 18, 2024	EX-10.3	Employment Agreement, dated as of November 18, 2024, by and between the Company and Hugh Davis. Exhibit 10.3 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Employment Agreement”), effective as of November 18, 2024 (“Agreement Effective Date”), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Employer”) and Hugh Davis (“Executive”). WHEREAS, Executive desires to provide services to Employer and Employer desires to retai
November 18, 2024	EX-10.2	Form of Registration Rights Agreement, dated November 18, 2024, by and between the Company and the investors named therein. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 18, 2024, is entered into by and among Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized ter
November 18, 2024	EX-99.2	Aclaris Therapeutics Announces $80 Million Private Placement Exhibit 99.2 Aclaris Therapeutics Announces $80 Million Private Placement WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS)(the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of
November 18, 2024	EX-10.5	Form of Stock Option Grant Notice and Option Agreement used in connection with the Aclaris Therapeutics, Inc. 2024 Inducement Plan. Exhibit 10.5 ACLARIS THERAPEUTICS, INC. 2024 INDUCEMENT PLAN STOCK OPTION GRANT NOTICE Aclaris Therapeutics, Inc. (the “Company”), pursuant to its 2024 Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notice, in the Opti
November 14, 2024	SC 13G/A	ACRS / Aclaris Therapeutics, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427061d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (the “Shar
November 6, 2024	10-Q	7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 6, 2024	EX-99.1	Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced; Top-line Data Anticipated in First Half of 2025 – Exhibit 99.1 Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced; Top-line Data Anticipated in First Half of 2025 – WAYNE, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on de
November 6, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commis
October 9, 2024	SC 13G/A	ACRS / Aclaris Therapeutics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 ACRSSC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ACLARIS THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 00461U105 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the
August 7, 2024	10-Q	7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 7, 2024	EX-99.1	Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update -Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis- -Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proc Exhibit 99.1 Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update -Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis- -Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds of up to $31.5 Million- WAYNE, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage bio
August 7, 2024	EX-10.1	Royalty Purchase Agreement, effective as of July 16, 2024, by and between the Registrant and OCM IP Healthcare Portfolio LP (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37581), filed with the SEC on August 7, 2024). EXHIBIT 10.1 EXECUTION VERSION CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN OMITTED. ROYALTY PURCHASE AGREEMENT ACLARIS THERAPEUTICS, INC. as Seller - and - OCM IP HEALTHCARE PORTFOLIO LP as Purchaser July 16, 2024 TABLE OF CONTEN
August 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commissi
July 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 Aclaris Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commissio
July 16, 2024	EX-99.1	Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million - Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Mi Exhibit 99.1 Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million - Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceuti
June 7, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commission
May 7, 2024	EX-99.2	© Copyright 2024 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Cautionary Note Regarding Forward-Looking Statements 2 Any statements contained in this presentation that do not desc Exhibit 99.2 © Copyright 2024 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Overview of ITK Portfolio May 7, 2024 EMPOWERING PATIENTS THROUGH KINOME INNOVATION © Copyright 2024 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Cautionary Note Regarding Forward-Loo
May 7, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Aclaris Therapeutics, Inc.
May 7, 2024	S-8	As filed with the U.S. Securities and Exchange Commission on May 7, 2024 As filed with the U.S. Securities and Exchange Commission on May 7, 2024 Registration No. 333-          UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ACLARIS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-0571712 (State or other jurisdiction of Incorporation or organiza
May 7, 2024	EX-99.1	Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - Exhibit 99.1 Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immu
May 7, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commission
May 7, 2024	10-Q	7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 25, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 25, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
March 19, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commissi
February 27, 2024	EX-4.1	Description of Securities. Exhibit 4.1 DESCRIPTION OF ACLARIS THERAPEUTICS, INC. CAPITAL STOCK The following description of the common stock of Aclaris Therapeutics, Inc., or the Company, is a summary and does not purport to be complete. This summary is qualified in its entirety by reference to the provisions of the Delaware General Corporation Law, or the DGCL, and the complete text of the Company’s amended and restated ce
February 27, 2024	EX-99.1	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update Exhibit 99.1 Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and
February 27, 2024	EX-97.1	Aclaris Therapeutics, Inc. Incentive Compensation Recoupment Policy, adopted as of October 2, 2023. Exhibit 97.1 ACLARIS THERAPEUTICS, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY 1.INTRODUCTION The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and the Board have determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation
February 27, 2024	EX-10.22	Letter Agreement, dated as of January 31, 2024, by and between the Registrant and Neal Walker (incorporated herein by reference to Exhibit 10.22 to the Registrant’s Annual Report on Form 10-K (File No. 001-37581), filed with the SEC on February 27, 2024). Exhibit 10.22 January 31, 2024 VIA EMAIL Neal Walker Dear Neal: This agreement contains the terms of your position as Interim Chief Executive Officer and President (the “Interim CEO”) of Aclaris Therapeutics, Inc. (the “Company”) with an effective date of January 17, 2024. As Interim CEO, you will report directly to the Board of Directors of the Company (the “Board”) and will perform such duties,
February 27, 2024	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Aclaris Therapeutics, Inc. Name of Subsidiary Jurisdiction of Incorporation or Organization Aclaris Life Sciences, Inc. Delaware Confluence Discovery Technologies, Inc. Delaware
February 27, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-37581 ACLARIS THERAPEUTICS, INC. Incorporated under the Laws of the I.R.S. Employer Identification No. State of Delaware 46-0571712 701 Lee Road
February 27, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commi
February 27, 2024	EX-10.15	Second Amended and Restated Employment Agreement, effective as of February 1, 2024, by and between the Registrant and Joseph Monahan (incorporated herein by reference to Exhibit 10.15 to the Registrant’s Annual Report on Form 10-K (File No. 001-37581), filed with the SEC on February 27, 2024). Exhibit 10.15 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Employment Agreement”), effective as of February 1, 2024 (“Agreement Effective Date”), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Employer”) and Joseph Monahan (“Executive”). WHEREAS, Executive is employ
February 27, 2024	EX-10.18	Separation Agreement, Waiver, and Release, dated as of February 4, 2024, by and between the Registrant and Douglas Manion (incorporated herein by reference to Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K (File No. 001-37581), filed with the SEC on February 27, 2024). Exhibit 10.18 SEPARATION AGREEMENT, WAIVER AND RELEASE THE SEPARATION AGREEMENT, WAIVER AND RELEASE (“Agreement”) is made and entered into as of 2/4/2024, by and among Douglas Manion, whose address is , and their heirs, legatees, personal representatives, successors and assigns (“Employee”), and Aclaris Therapeutics, Inc. (“Aclaris” or “Employer”). WHEREAS, Employer and Employee are parties to tha
February 14, 2024	SC 13G/A	ACRS / Aclaris Therapeutics, Inc. / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246235d22sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 00461U105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Che
February 14, 2024	SC 13G/A	ACRS / Aclaris Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 00461U105 (CUSIP Num
February 14, 2024	SC 13G/A	ACRS / Aclaris Therapeutics, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (the “Shares”) (Title of Class of Securities) 00461U
February 14, 2024	SC 13G/A	ACRS / Aclaris Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm245429d10sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ACLARIS THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 00461U105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statem
February 14, 2024	SC 13G/A	ACRS / Aclaris Therapeutics, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 b110242sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 00461U105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check
February 14, 2024	SC 13G	ACRS / Aclaris Therapeutics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 ACRSSC13GFeb24.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ACLARIS THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 00461U105 (CUSIP Number) FEBRUARY 5, 2024 (Date of event which requires filing of this statement) Check the appropriate box to
February 14, 2024	SC 13G/A	ACRS / Aclaris Therapeutics, Inc. / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 13, 2024	SC 13G/A	ACRS / Aclaris Therapeutics, Inc. / Foresite Capital Fund IV, L.P. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 4)* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 00461U105 (CUSIP Number) December 31, 2023 (Date
February 13, 2024	SC 13G	ACRS / Aclaris Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Aclaris Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 00461U105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b)
February 8, 2024	SC 13G/A	ACRS / Aclaris Therapeutics, Inc. / BML Investment Partners, L.P. Passive Investment SC 13G/A 1 acrs13g020724.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 1 )* Aclaris Therapeutics Inc (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 00461U105 (CUSIP N
February 5, 2024	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2024 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of in
February 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 Aclaris Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commis
February 1, 2024	SC 13G/A	ACRS / Aclaris Therapeutics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ACLARIS THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 00461U105 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate
January 19, 2024	EX-99.1	Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review Exhibit 99.1 Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review – Douglas Manion, M.D. to step down as Chief Executive Officer, President and Member of Board of Directors – – Dr. Neal Walker, Current Chairman and Co-founder, Appointed as Interim Chief Executive Officer – WAYNE, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-
January 19, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2024 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commis
January 16, 2024	SC 13G	ACRS / Aclaris Therapeutics, Inc. / BML Investment Partners, L.P. Passive Investment SC 13G 1 bml13g.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. )* Aclaris Therapeutics Inc (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 00461U105 (CUSIP Number) Janu
December 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 Aclaris Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commi
December 19, 2023	EX-99.1	Aclaris Therapeutics Provides Corporate Update - ATI-1777 Phase 2a Trial Results Published in JID Innovations - - ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 - - Aclaris Announces Reduction in Workforce - Exhibit 99.1 Aclaris Therapeutics Provides Corporate Update - ATI-1777 Phase 2a Trial Results Published in JID Innovations - - ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 - - Aclaris Announces Reduction in Workforce - WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel dr
December 11, 2023	SC 13G	ACRS / Aclaris Therapeutics Inc / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 ACRSSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ACLARIS THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 00461U105 (CUSIP Number) DECEMBER 7, 2023 (Date of event which requires filing of this statement) Check the appropriate box to desig
December 11, 2023	SC 13G/A	ACRS / Aclaris Therapeutics Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00461U105 (CUSIP Number) November 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
November 24, 2023	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.00001 par value per share, of Aclaris Therapeutics, Inc. and further agree to the filing of this agreement as an exhibit
November 24, 2023	SC 13G	ACRS / Aclaris Therapeutics Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Aclaris Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commi
November 13, 2023	EX-99.1	© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Cautionary Note Regarding Forward-Looking Statements 2 Any statements contained in this presentation that do not desc Exhibit 99.1 © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Zunsemetinib (ATI-450) Phase 2b Rheumatoid Arthritis Trial Top-line Results November 13, 2023 EMPOWERING PATIENTS THROUGH KINOME INNOVATION © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All ri
November 13, 2023	EX-99.2	Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update -Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheuma Exhibit 99.2 Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update -Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis – -Efficacy Results Do Not Support Further Development of Zunsemetinib – -Company to Host Conference Call and Webcast Toda
November 6, 2023	EX-99.1	Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update - Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month – - Completion of Enrollment in ATI-1777 Phase 2b Trial in A Exhibit 99.1 Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update - Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month – - Completion of Enrollment in ATI-1777 Phase 2b Trial in Atopic Dermatitis As Previously Announced; Topline Data Anticipated Around Year-End 2023 - WAYNE, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) - Ac
November 6, 2023	10-Q	7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 6, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commis
September 18, 2023	EX-99.2	© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Cautionary Note Regarding Forward-Looking Statements 2 Any statements contained in this presentation that do not desc Exhibit 99.2 © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) EMPOWERING PATIENTS THROUGH KINOME INNOVATION 18 Sep 2023 ATI-2138: An Investigational Novel Covalent ITK-JAK3 Inhibitor for T-Cell Mediated Diseases © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, I
September 18, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Comm
September 18, 2023	EX-99.1	Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor - Preliminary Data Support Progression to Phase 2a Proof of Concept Trials in T cell-mediated Exhibit 99.1 Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor - Preliminary Data Support Progression to Phase 2a Proof of Concept Trials in T cell-mediated Autoimmune Diseases - WAYNE, Pa., Sep. 18, 2023 (GLOBE NEWSWIRE) – Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmac
September 5, 2023	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Aclaris Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the unde
September 5, 2023	SC 13G	ACRS / Aclaris Therapeutics Inc / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (the “Shares”) (Title of Class of Securities) 00461U1
August 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commissi
August 7, 2023	EX-99.1	Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update - Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced; Data Expected in Q4 2023 – Exhibit 99.1 Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update - Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced; Data Expected in Q4 2023 – WAYNE, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing n
August 7, 2023	10-Q	7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 7, 2023	EX-3.2	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37581), filed with the SEC on August 7, 2023). Exhibit 3.2 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACLARIS THERAPEUTICS, INC. ACLARIS THERAPEUTICS, INC., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: FIRST:The name of the Company is Aclaris Therapeutics, Inc. SECOND:The Company’s original Certificate of Incorporation was fil
June 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Aclaris Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commission
June 12, 2023	EX-10.1	Amended and Restated Employment Agreement, effective as of July 1, 2023, by and between the Registrant and Joseph Monahan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on June 12, 2023). EXHIBIT 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Employment Agreement”), effective as of July 1, 2023 (“Agreement Effective Date”), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Employer”) and Joseph Monahan (“Executive”). WHEREAS, Executive is employed by and performin
June 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 Aclaris Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commission
June 1, 2023	EX-10.1	Office Lease, dated May 26, 2023, by and between the Registrant and CBCC – Lee Road Acquisitions, LLC (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on June 1, 2023). (a Delaware limited liability company) (a Delaware corporation) Rentable Square Feet First Floor – Suite 103 Chesterbrook Corporate Center 701 Lee Road Wayne, Pennsylvania Exhibit 10.
June 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 Aclaris Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commission
May 8, 2023	10-Q	7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 8, 2023	S-8	As filed with the U.S. Securities and Exchange Commission on May 8, 2023 As filed with the U.S. Securities and Exchange Commission on May 8, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ACLARIS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-0571712 (State or other jurisdiction of Incorporation or organization) (I.
May 8, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commission
May 8, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Aclaris Therapeutics, Inc.
May 8, 2023	EX-99.2	© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved Cautionary Note Regarding Forward-Looking Statements 2 Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as th Exhibit 99.2 © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved May 8, 2023 Q1 2023 Investor Conference Call © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved Cautionary Note Regarding Forward-Looking Statements 2 Any statements contained in this presentation that do not describe historical facts may constit
May 8, 2023	EX-99.1	Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update - Management to Host Conference Call at 8:00 AM ET Today – Exhibit 99.1 Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update - Management to Host Conference Call at 8:00 AM ET Today – WAYNE, Pa., May 8, 2023 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its fin
May 8, 2023	EX-10.4	Ninth Amended and Restated Non-Employee Director Compensation Policy (incorporated herein by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37581), filed with the SEC on May 8, 2023). Exhibit 10.4 ACLARIS THERAPEUTICS, INC. NINTH AMENDED & RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Aclaris Therapeutics, Inc. (the “Company”) (each such member, an “Eligible Director”) will receive the compensation described in this Ninth Amended & Restated Non-Employee Director Compensation Polic
April 20, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 20, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
April 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2023 Aclaris Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commissi
April 14, 2023	EX-99.1	© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Cautionary Note Regarding Forward-Looking Statements 2 Any statements contained in this presentation that do not desc Exhibit 99.1 © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Corporate Overview April 2023 EMPOWERING PATIENTS THROUGH KINOME INNOVATION © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Cautionary Note Regarding Forward-Looking Sta
April 10, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 10, 2023	SC 13G/A	ACRS / Aclaris Therapeutics Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00461U105 (CUSIP Number) March 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
March 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Aclaris Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commissi
March 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 Aclaris Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commissi
March 27, 2023	EX-10.1	Amendment No. 1 to Consulting Services Agreement, dated as of March 23, 2023, by and between the Company and Frank Ruffo. Exhibit 10.1 AMENDMENT NO. 1 TO CONSULTING SERVICES AGREEMENT This Amendment No. 1 (this “Amendment”), is made and entered into as of March 23, 2023, by and between Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”) and Frank Ruffo (“Consultant”). WHEREAS, the Company and Consultant entered into that certain Consulting Services Agreement, dated as of January 1, 2023 (the “Agreement
March 16, 2023	SC 13G	ACRS / Aclaris Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 00461U105 (CUSIP Numb
March 16, 2023	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 16, 2023 with respect to the Common Stock, par value $0.00001 per share, of Aclaris Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance
March 6, 2023	EX-99.1	Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa - Study Did Not Meet Primary or Secondary Efficacy Endpoints in Hidradenitis Suppurativ Exhibit 99.1 Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa - Study Did Not Meet Primary or Secondary Efficacy Endpoints in Hidradenitis Suppurativa - Overall Safety Profile and PK/PD Generally Consistent with Observations in Prior Studies of Zunsemetinib WAYNE, Pa., Mar. 6, 2023 (GL
March 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 Aclaris Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commissio
February 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Aclaris Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commi
February 23, 2023	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Aclaris Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities EX-FILING FEES 2 tm237504d2ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Aclaris Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit M
February 23, 2023	EX-10.23	Amended and Restated Employment Agreement, dated as of January 1, 2023, by and between the Registrant and Douglas Manion (incorporated herein by reference to Exhibit 10.23 to the Registrant’s Annual Report on Form 10-K (File No. 001-37581), filed with the SEC on February 23, 2023). Exhibit 10.23 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Employment Agreement”), effective as of January 1, 2023 (“Agreement Effective Date”), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Employer”) and Douglas Manion (“Executive”). WHEREAS, Executive desires to continue to p
February 23, 2023	EX-10.19	Consulting Agreement, dated as of January 1, 2023, by and between the Registrant and Frank Ruffo. Exhibit 10.19 CONSULTING SERVICES AGREEMENT THIS CONSULTING SERVICES AGREEMENT (this “Agreement”), is made and entered into as of January 1, 2023 (the “Effective Date”), by and between Aclaris Therapeutics, Inc., a Delaware corporation, with an address of 640 Lee Road, Suite 200, Wayne, Pennsylvania 19087 (together with its wholly owned subsidiaries, the “Company”) and Frank Ruffo, an individual,
February 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Aclaris Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Aclaris Therapeutics, Inc.
February 23, 2023	EX-10.12	Eighth Amended and Restated Non-Employee Director Compensation Policy (incorporated herein by reference to Exhibit 10.12 to the Registrant’s Annual Report on Form 10-K (File No. 001-37581), filed with the SEC on February 23, 2023). Exhibit 10.12 ACLARIS THERAPEUTICS, INC. EIGHTH AMENDED & RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Aclaris Therapeutics, Inc. (the “Company”) (each such member, an “Eligible Director”) will receive the compensation described in this Eighth Amended & Restated Non-Employee Director Compensation Po
February 23, 2023	EX-10.18	Separation Agreement and General Release, dated as of December 9, 2022, by and between the Registrant and Frank Ruffo. Exhibit 10.18 December 9, 2022 Frank Ruffo RE: Separation Agreement and General Release Dear Frank, This letter is intended to set forth the terms of your separation from employment with Aclaris Therapeutics, Inc. and your general release and waiver of claims in favor of Aclaris Therapeutics, Inc., and its parents, subsidiaries, affiliates, and all related corporate entities and partnerships, and
February 23, 2023	EX-99.1	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update Exhibit 99.1 Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update WAYNE, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and
February 23, 2023	EX-10.1	Sales Agreement, dated as of February 23, 2023, by and among the Registrant, SVB Securities LLC and Cantor Fitzgerald & Co. (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on February 23, 2023). Exhibit 10.1 ACLARIS THERAPEUTICS, INC. Shares of Common Stock ($0.00001 par value per share) SALES AGREEMENT February 23, 2023 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 Ladies and Gentlemen: Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms an
February 23, 2023	424B5	$200,000,000 Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-256337 PROSPECTUS SUPPLEMENT $200,000,000 Common Stock We have entered into a sales agreement with SVB Securities LLC, or SVB Securities, and Cantor Fitzgerald & Co., or Cantor, relating to shares of our common stock offered by this prospectus supplement. In accordance with the terms of the sales agreement, we may offer and
February 23, 2023	EX-10.16	Letter Agreement, dated as of November 22, 2022, by and between the Registrant and Neal Walker. Exhibit 10.16 11/22/2022 Neal Walker Dear Neal: In connection with your resignation from employment from Chief Executive Officer effective as of December 31, 2022 (the “Retirement Date”) and transition to Chair of the Board of Directors (the “Board”) of Aclaris Therapeutics, Inc. (the “Company”) effective as of January 1, 2023, you acknowledge and agree to the following changes to the equity award
February 23, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Commission file number 001-37581 ACLARIS THERAPEUTICS, INC. Incorporated under the Laws of the I.R.S. Employer Identification No. State of Delaware 46-0571712 640 Lee Road
February 23, 2023	EX-10.24	Employment Agreement, dated as of January 1, 2023, by and between the Registrant and Kevin Balthaser (incorporated herein by reference to Exhibit 10.24 to the Registrant’s Annual Report on Form 10-K (File No. 001-37581), filed with the SEC on February 23, 2023). Exhibit 10.24 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Employment Agreement”), effective as of January 1, 2023 (“Agreement Effective Date”), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Employer”) and Kevin Balthaser (“Executive”). WHEREAS, Executive desires to provide services to Employer and Employer desires to r
February 23, 2023	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Aclaris Therapeutics, Inc. Name of Subsidiary Jurisdiction of Incorporation or Organization Aclaris Therapeutics International Limited United Kingdom Aclaris Life Sciences, Inc. Delaware Confluence Discovery Technologies, Inc. Delaware
February 14, 2023	SC 13G/A	ACRS / Aclaris Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga107422acrs02142023.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0
February 14, 2023	SC 13G/A	ACRS / Aclaris Therapeutics Inc / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 13, 2023	SC 13G/A	ACRS / Aclaris Therapeutics Inc / Foresite Capital Fund IV, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236260d4sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 3)* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 00461U1
February 6, 2023	SC 13G/A	ACRS / Aclaris Therapeutics Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00461U105 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 9, 2023	EX-99.1	© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) Cautionary Note Regarding Forward - Looking Statements 2 Any statements contained in this pres Exhibit 99.1 © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP - US - 0782 1/09) 41 st Annual J.P. Morgan Healthcare Conference January 2023 EMPOWERING PATIENTS THROUGH KINOME INNOVATION © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights re
January 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Aclaris Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commiss
January 6, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): December 31, 2022 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware ? 001-37581 ? 46-0571712 (State or other jurisdiction of incorporation
December 13, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): December 9, 2022 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware ? 001-37581 ? 46-0571712 (State or other jurisdiction of incorporation)
November 22, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 18, 2022 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware ? 001-37581 ? 46-0571712 (State or other jurisdiction of incorporation
November 8, 2022	EX-99.1	Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update - Completed Enrollment in Phase 2a Trial of Zunsemetinib in Hidradenitis Suppurativa; Topline Data Expected in Mid-first Half of 2023 - Announced Patent Exhibit 99.1 Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update ? - Completed Enrollment in Phase 2a Trial of Zunsemetinib in Hidradenitis Suppurativa; Topline Data Expected in Mid-first Half of 2023 ? - Announced Patent License Agreement with Lilly for the Treatment of Alopecia Areata with Proceeds of $17.6 million ? - Successfully Completed ATI-2138
November 8, 2022	10-Q	7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? 7 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 8, 2022	EX-99.2	© Copyright 2022 Aclaris Therapeutics, Inc. All rights reserved Any statements contained in this presentation that do not describe historical facts may constitute forward - looking statements as that term is defined in the Private Securities Litigati EX-99.2 3 acrs-20221108xex99d2.htm EX-99.2 Exhibit 99.2 © Copyright 2022 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2022 Aclaris Therapeutics, Inc. All rights reserved November 8, 2022 EMPOWERING PATIENTS THROUGH KINOME INNOVATION Phase 1 Single Ascending Dose (SAD) Trial of ATI - 2138, an Investigational Oral Covalent ITK/TXK/JAK3 (ITJ) Inhibitor Preliminary Data © Copyright 2022
November 8, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 8, 2022 ? ? Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware ? 001-37581 ? 46-0571712 (State or other jurisdic
August 3, 2022	EX-10.1	Employment Agreement, dated as of June 27, 2022, by and between the Registrant and Gail Cawkwell (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37581), filed with the SEC on August 3, 2022). Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Employment Agreement”), effective as of June 27, 2022 (“Agreement Effective Date”), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Employer”) and Gail Cawkwell (“Executive”). WHEREAS, Executive desires to provide services to Employer and Employer desires to retain
August 3, 2022	EX-99.1	Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update EX-99.1 2 acrs-20220803xex99d1.htm EX-99.1 Exhibit 99.1 Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update ● Appointed Douglas Manion, M.D., FRCP (C), as President and COO ● Initiated Phase 2a Study Activities for Psoriatic Arthritis WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceut
August 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commissi
August 3, 2022	10-Q	7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 1, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 1, 2022 ? ? Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware ? 001-37581 ? 46-0571712 (State or other jurisdicti
August 1, 2022	EX-10.1	Employment Agreement, dated as of August 1, 2022, by and between the Registrant and Douglas Manion (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on August 1, 2022). Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Employment Agreement?), effective as of August 1, 2022 (?Agreement Effective Date?), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (?Employer?) and Douglas Manion (?Executive?). WHEREAS, Executive desires to provide services to Employer and Employer desires to reta
June 3, 2022	8-K	Submission of Matters to a Vote of Security Holders ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 2, 2022 ? ? Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware ? 001-37581 ? 46-0571712 (State or other jurisdiction
May 10, 2022	10-Q	7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? 7 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 10, 2022 ? ? Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware ? 001-37581 ? 46-0571712 (State or other jurisdiction
May 10, 2022	S-8	As filed with the U.S. Securities and Exchange Commission on May 10, 2022 As filed with the U.S. Securities and Exchange Commission on May 10, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ACLARIS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-0571712 (State or other jurisdiction of Incorporation or organization) (I
May 10, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Aclaris Therapeutics, Inc.
May 10, 2022	EX-99.1	Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update Exhibit 99.1 Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update ? ? Clinical Sites Activated for Phase 2b Trial of ATI-1777 ? ? April Capital Raise Extends Cash Runway Through End of 2025 ? WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug
April 25, 2022	SC 13G	ACRS / Aclaris Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ACLARIS THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 00461U105 (CUSIP Number) April 13, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
April 21, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 21, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?
April 14, 2022	8-K	Regulation FD Disclosure ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): April 13, 2022 ? ? Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware ? 001-37581 ? 46-0571712 (State or other jurisdicti
February 24, 2022	EX-10.16	Employment Agreement, dated as of January 31, 2022, by and between the Registrant and James Loerop (incorporated herein by reference to Exhibit 10.16 to the Registrant’s Annual Report on Form 10-K (File No. 001-37581), filed with the SEC on February 24, 2022). Exhibit 10.16 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Employment Agreement?), effective as of January 31, 2022 (?Agreement Effective Date?), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (?Employer?) and James Loerop (?Executive?). WHEREAS, Executive desires to provide services to Employer and Employer desires to ret
February 24, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commi
February 24, 2022	EX-10.12	Sixth Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.12 ACLARIS THERAPEUTICS, INC. SIXTH AMENDED & RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of Aclaris Therapeutics, Inc. (the ?Company?) (each such member, an ?Eligible Director?) will receive the compensation described in this Sixth Amended & Restated Non-Employee Director Compensation Poli
February 24, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 24, 2022	EX-10.23	Seventh Amended and Restated Non-Employee Director Compensation Policy (incorporated herein by reference to Exhibit 10.23 to the Registrant’s Annual Report on Form 10-K (File No. 001-37581), filed with the SEC on February 24, 2022). Exhibit 10.23 ACLARIS THERAPEUTICS, INC. SEVENTH AMENDED & RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of Aclaris Therapeutics, Inc. (the ?Company?) (each such member, an ?Eligible Director?) will receive the compensation described in this Seventh Amended & Restated Non-Employee Director Compensation
February 24, 2022	EX-99.1	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update Exhibit 99.1 Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update ? WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter an
February 24, 2022	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Aclaris Therapeutics, Inc. Name of Subsidiary Jurisdiction of Incorporation or Organization Aclaris Therapeutics International Limited United Kingdom Aclaris Life Sciences, Inc. Delaware Confluence Discovery Technologies, Inc. ? Delaware ?
February 24, 2022	EX-10.18	Severance Agreement and General Release, dated as of January 7, 2022, by and between the Registrant and David Gordon (incorporated herein by reference to Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K (File No. 001-37581), filed with the SEC on February 24, 2022). Exhibit 10.18 ? ? ? ? January 7, 2022 ? David Gordon ? ? ? ? ? RE: Severance Agreement and General Release Dear David: This letter is intended to set forth the terms of your separation from employment with Aclaris Therapeutics, Inc. and your general release and waiver of claims in favor of Aclaris Therapeutics, Inc., and its parents, subsidiaries, affiliates, and all related corporate entities and
February 24, 2022	EX-10.17	Severance Agreement and General Release, dated as of November 1, 2021, by and between the Registrant and Kamil Ali-Jackson. Exhibit 10.17 ? ? ? November 1, 2021 ? ? ? ? RE: Severance Agreement and General Release Dear This letter is intended to set forth the terms of your separation from employment with Aclaris Therapeutics, Inc. and your general release and waiver of claims in favor of Aclaris Therapeutics, Inc., and its parents, subsidiaries, affiliates, and all related corporate entities and partnerships, and their
February 24, 2022	EX-10.15	Employment Agreement, dated as of January 12, 2022, by and between the Registrant and Joseph Monahan (incorporated herein by reference to Exhibit 10.15 to the Registrant’s Annual Report on Form 10-K (File No. 001-37581), filed with the SEC on February 24, 2022). Exhibit 10.15 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Employment Agreement?), effective as of January 12, 2022 (?Agreement Effective Date?), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (?Employer?) and Joseph Monahan (?Executive?). WHEREAS, Executive desires to continue to provide services to Employer and Employer
February 15, 2022	SC 13G/A	ACRS / Aclaris Therapeutics Inc / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2022	SC 13G	ACRS / Aclaris Therapeutics Inc / Venrock Healthcare Capital Partners II, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 00461U105 (CUSIP Number) January 19, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p
February 11, 2022	SC 13G/A	ACRS / Aclaris Therapeutics Inc / Foresite Capital Fund III, L.P. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 00461U105 (CUSIP Number) December 31, 2021 (Date
February 10, 2022	SC 13G/A	ACRS / Aclaris Therapeutics Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - ACLARIS THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 00461U105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p
February 4, 2022	SC 13G	ACRS / Aclaris Therapeutics Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00461U105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
January 24, 2022	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated January 24, 2022 with respect to the Common Stock, $0.00001 par value per share of Aclaris Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordanc
January 24, 2022	SC 13G	ACRS / Aclaris Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Aclaris Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 00461U105 (CUSIP Numb
January 14, 2022	EX-10.2	Amended and Restated Employment Agreement, dated as of January 12, 2022, by and between the Registrant and Frank Ruffo (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on January 14, 2022). Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Employment Agreement?), effective as of January 12, 2022 (?Agreement Effective Date?), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (?Employer?) and Frank Ruffo (?Executive?). WHEREAS, Executive desires to continue to prov
January 14, 2022	EX-10.1	Amended and Restated Employment Agreement, dated as of January 12, 2022, by and between the Registrant and Neal Walker (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on January 14, 2022). Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Employment Agreement?), effective as of January 12, 2022 (?Agreement Effective Date?), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (?Employer?) and Neal Walker (?Executive?). WHEREAS, Executive desires to continue to prov
January 14, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): January 12, 2022 ? ? Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware ? 001-37581 ? 46-0571712 (State or other jurisdic
December 7, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): December 7, 2021 ? ? Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware ? 001-37581 ? 46-0571712 (State or other jurisdic
December 7, 2021	EX-99.1	© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2021 Aclaris Therapeutics, Inc. All rights reserved (PP--US-0589 06/21) © Copyright 2021 Aclaris Therapeutics, Inc. All rights reserved (PP--US-0677 12/21) Aclaris Thera Exhibit 99.1 ? Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) ? Copyright 2021 Aclaris Therapeutics, Inc. All rights reserved (PP-US-0589 06/21) ? Copyright 2021 Aclaris Therapeutics, Inc. All rights reserved (PP-US-0677 12/21) Aclaris Therapeutics Virtual R&D Day The Productivity of the Platform December 7, 2021 EMPOWERING PATIENTS THROUGH KINOME INNOVATION ? Copyright 2020 Ac
November 2, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 1, 2021 ? ? Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware ? 001-37581 ? 46-0571712 (State or other jurisdic
November 2, 2021	10-Q	7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? 7 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 2, 2021	EX-99.1	Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update Exhibit 99.1 ? Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update ? ? ? Investigational New Drug Application for ATI-2138 for the Treatment of Psoriasis Submitted in October 2021 ? ? Planning to Initiate Phase 2b Trial of Zunsemetinib (ATI-450) in Moderate to Severe Rheumatoid Arthritis in the Fourth Quarter of 2021 ? WAYNE, Pa., Nov. 02, 2021 (GLOBE
August 27, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 27, 2021 ? ? Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware ? 001-37581 ? 46-0571712 (State or other jurisdict
August 27, 2021	EX-99.1	UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK Exhibit 99.1 ? UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ? ? IN RE ACLARIS THERAPEUTICS, INC. DERIVATIVE LITIGATION ? Lead Case No. 1:19-cv-10641-LJL ? NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE ACTION ? TO: ALL OWNERS OF THE COMMON STOCK OF ACLARIS THERAPEUTICS, INC. ("ACLARIS" OR THE "COMPANY") CURRENTLY AND AS OF JULY 29, 2021 ("APPLICABLE ACLARIS STOC
August 27, 2021	EX-99.2	UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK Exhibit 99.2 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ? ? IN RE ACLARIS THERAPEUTICS, INC. DERIVATIVE LITIGATIoN ? Lead Case No. 1:19-cv-10641-LJL STIPULATION AND AGREEMENT OF SETTLEMENT This Stipulation and Agreement of Settlement ("Stipulation") is made and entered into by the following Settling Parties (as defined herein), each by and through their respective counsel: (1) plai
August 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 5, 2021 ? ? Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware ? 001-37581 ? 46-0571712 (State or other jurisdicti
August 5, 2021	EX-99.1	Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update Exhibit 99.1 Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update ? ? ? ? ? ? Public Offering with Net Proceeds of $134.9 Million in June Strengthens Balance Sheet and Extends Cash Runway Through the End of 2024 ? ? ? Positive Preliminary Topline Data for Phase 2a Trial of ATI-1777 in Moderate to Severe Atopic Dermatitis Announced in June ? ? ? Advanci
August 5, 2021	10-Q	7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? 7 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 5, 2021	EX-10.1	Fifth Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.1 ACLARIS THERAPEUTICS, INC. FIFTH AMENDED & RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of Aclaris Therapeutics, Inc. (the ?Company?) (each such member, an ?Eligible Director?) will receive the compensation described in this Fifth Amended & Restated Non-Employee Director Compensation Polic
July 26, 2021	8-K	Termination of a Material Definitive Agreement ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): July 23, 2021 ? ? Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware ? 001-37581 ? 46-0571712 (State or other jurisdictio
June 11, 2021	EX-99.2	Aclaris Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Aclaris Announces Pricing of Public Offering of Common Stock WAYNE, Pa., June 9, 2021 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 7,042,254 shares of its common stock at a price to t
June 11, 2021	EX-1.1	Underwriting Agreement by and among Aclaris Therapeutics, Inc., Jefferies LLC, SVB Leerink LLC and Piper Sandler & Co., dated June 9, 2021. Exhibit 1.1 Execution Version 7,042,254 Shares Aclaris Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENT June 9, 2021 JEFFERIES LLC SVB LEERINK LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o SVB LEERINK LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o PIPER SANDLER & CO. 800 Nicollet Ma
June 11, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commission
June 11, 2021	EX-99.1	Aclaris Announces Proposed Public Offering of Common Stock Exhibit 99.1 Aclaris Announces Proposed Public Offering of Common Stock WAYNE, Pa., June 8, 2021 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it intends to offer and sell, subject to market conditions, $75 million in shares of its common sto
June 10, 2021	424B5	CALCULATION OF REGISTRATION FEE TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-256337? CALCULATION OF REGISTRATION FEE ? ? ? ? ? Title of Each Class of Securities to be Registered ? ? Amount Registered(1) ? ? Proposed Maximum Offering Price Per Unit(2) ? ? Proposed Maximum Aggregate Offering Price(1) ? ? Amount of Registration Fee(2) ? Common stock, par value $0.00001 ? ? ? ? 8,098,592 ? ? ? ? $ 17.75 ?
June 8, 2021	424B5	$75,000,000 Common Stock TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.
June 8, 2021	EX-99.2	Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis Exhibit 99.2 Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis ? ? ? ? ATI-1777 Achieved Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 ? Minimal Systemic Exposure Supports ?Soft? Topical JAK Inhibitor Approach ? ATI-1777 was Generally Well Tolerated ? Data Support Progression to Ph
June 8, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 8, 2021 ? ? Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware ? 001-37581 ? 46-0571712 (State or other jurisdiction
June 8, 2021	EX-99.1	© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2021 Aclaris Therapeutics, Inc. All rights reserved (PP--US-0589 06/21) © Copyright 2021 Aclaris Therapeutics, Inc. All rights reserved (PP--US-0602 06/21) ATI-1777-AD-2 Exhibit 99.1 ? Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) ? Copyright 2021 Aclaris Therapeutics, Inc. All rights reserved (PP-US-0589 06/21) ? Copyright 2021 Aclaris Therapeutics, Inc. All rights reserved (PP-US-0602 06/21) ATI-1777-AD-201 (Investigational Compound) Preliminary Topline Data June 8, 2021 EMPOWERING PATIENTS THROUGH KINOME INNOVATION ? Copyright 2020 Aclaris
June 3, 2021	8-K	Submission of Matters to a Vote of Security Holders ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 3, 2021 ? ? Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware ? 001-37581 ? 46-0571712 (State or other jurisdiction
May 20, 2021	EX-4.6	Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.6 4 tm2116900d2ex4-6.htm EXHIBIT 4.6 Exhibit 4.6 ACLARIS THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ACLARIS THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ACLARIS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [·], a [corporati
May 20, 2021	EX-4.5	Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.5 3 tm2116900d2ex4-5.htm EXHIBIT 4.5 Exhibit 4.5 ACLARIS THERAPEUTICS, INC. AND                               , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF                  ACLARIS THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ACLARIS THERAPEUTICS, INC., a Delaware corporation
May 20, 2021	S-3ASR	As filed with the Securities and Exchange Commission on May 20, 2021 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 20, 2021 Registration No.
May 20, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 20, 2021 Aclaris Therapeutics, Inc.
May 20, 2021	EX-4.7	Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.7 5 tm2116900d2ex4-7.htm EXHIBIT 4.7 Exhibit 4.7 ACLARIS THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ACLARIS THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [·], between ACLARIS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [·], a [corporati
May 20, 2021	EX-10.1	Sales Agreement, dated May 20, 2021, by and among the Registrant, SVB Leerink LLC and Cantor Fitzgerald & Co. (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on May 20, 2021). Exhibit 10.1 ACLARIS THERAPEUTICS, INC. Shares of Common Stock ($0.00001 par value per share) SALES AGREEMENT May 20, 2021 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 Ladies and Gentlemen: Aclaris Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and condit
May 20, 2021	EX-4.3	Form of Indenture, between the Registrant and one or more trustees to be named. EX-4.3 2 tm2116900d2ex4-3.htm EXHIBIT 4.3 Exhibit 4.3 ACLARIS THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 20    Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Fo
May 7, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2021 Aclaris Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37581 46-0571712 (State or other jurisdiction of incorporation) (Commission
May 7, 2021	10-Q	Quarterly Report - 10-Q Table of Contents ? 7 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

ACRS / Aclaris Therapeutics, Inc. - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

मूलभूत आँकड़े

SEC Filings

SEC Filings (Chronological Order)

Other Listings